Dennis Bruemmer, MD, PhD

Appointed
2019

Education & Fellowships

Fellowship - University of Kentucky Chandler Medical Center
Cardiovascular Disease
Lexington, KY
2015

Fellowship - University of Kentucky Chandler Medical Center
Endocrinology, Diabetes and Metabolism
Lexington, KY
2009

Fellowship - University of California Los Angeles
Postdoctoral Research Molecular Biology
Los Angeles, CA
2003

Residency - Humboldt University Berlin, Charité/Robert Virchow Hospital/German Heart Institute
Internal Medicine
Germany
2001

Medical Education - University of Hamburg, Germany
Hamburg, Germany
1998

Certifications

• Internal Medicine
• Internal Medicine - Cardiovascular Disease
• Internal Medicine - Endocrinology, Diabetes and Metabolism

Specialty Interests

General cardiology, preventive cardiology, diabetes management in cardiac (heart) patients, cardiac intensive care, echocardiography

Awards & Honors

• 2017  Heart and Vascular Institute/Vascular Medicine Institute Innovator Award, University of Pittsburgh
• 2014 Henry I. Russek Award, American College of Cardiology
• 2014 Investigator Award, American College of Cardiology
• 2009 Novo Nordisk Scholarship Award, American Association of Clinical Endocrinology
• 2008 Career Development Award, American Diabetes Association
• 2004 ATVB Merit Award for Young Investigators, American Heart Association
• 2004 Young Scholar Award, American Society of Hypertension
• 2004 Irvine H. Page Young Investigator Research Award, American Heart Association
• 2004 National Scientist Development Award, American Heart Association
• 2003 Young Investigator Award, The Endocrine Society
• 2003 Young Investigator Award Basic Science (1. Prize), European Society of Cardiology
• 2002 New Investigator Award, High Blood Pressure Council, American Heart Association
• 2001 Cardiovascular Young Investigator Award, AstraZeneca

See publications for Dennis Bruemmer, MD, PhD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 4/30/2025, Dr. Bruemmer has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Bruemmer receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Bayer Healthcare Pharmaceuticals, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.